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Abstract
The Kearns-Sayre syndrome is a mitochondrial disorder (generally due to mitochondrial DNA deletions) that causes
ophthalmoplegia, retinopathy, ataxia and brain abnormalities such as leukoencephalopathy. In this syndrome, the
choroid plexus epithelial cells, unlike brain cells, are greatly enlarged and granular, consistent with their inability to
adequately transport folate from blood into cerebrospinal fluid (CSF), and homovanillic acid (a dopamine metabo-
lite) from CSF into blood. This inability to transport folates from blood into CSF (and brain) adequately, causes cere-
bral folate deficiency that can be partially reversed by very high doses of reduced folates. The Kearns-Sayre
syndrome is a disease that interferes with key choroid plexus functions and is a cause of generalized choroid
plexus failure.
Introduction
Besides secreting most of the cerebrospinal fluid (CSF),
the choroid plexus (CP) epithelial cells, a locus of the
blood-CSF barrier, like renal tubule cells, have myriad
other functions. These include the active transport of
essential micronutrients into CSF from blood, e.g.,
methyltetrahydrofolic acid (MeTHF) and ascorbic acid
(AA) [1]. From CSF, these micronutrients enter mam-
malian brain [1]. The CP also transports many exogen-
ous chemicals and waste products of metabolism, e.g.,
homovanillic acid (HVA) an end product of dopamine
metabolism in brain, out of CSF.
In recent years, the mechanisms responsible for some
of these functions of the CP have been worked out on a
molecular basis. For example, the vectorial transport of
MeTHF (the principal folate in plasma and CSF) from
blood into CSF via the CP is due to a three-part active
transport system in series: first, the folate receptor alpha
(FRa) transfers MeTHF from blood into CP endosomes;
then MeTHF is released from the endosomes into the
CP cytoplasm by the proton-coupled folate transporter
(PCFT); and finally MeTHF is released from the cyto-
plasm into CSF by facilitated diffusion via the reduced
folate carrier (RFC) [1]. Another example is AA that is
transported into CP from blood by the active sodium-
dependent vitamin C-2 transporter (SVCT-2); how AA
effluxes from CP into CSF is unknown. It is worth not-
ing that the concentrations of vitamin C and MeTHF in
CSF are about 3-4 times higher than the plasma concen-
trations, thus highlighting the active (energy-requiring)
nature of these processes [1]. Finally, HVA is trans-
ported by CP out of CSF by the organic acid transporter
3 (OAT-3).
The principal objective of this paper is to answer a
question we asked about thirty years ago: Can the CP
fail as an organ in a generalized way in disease states
[2]? If so, we predicted then that the clinical result
would be devastating, since the CP has essential func-
tions [2]. We think that the Kearns-Sayre syndrome
(KSS) is apparently the first clear example of generalized
CP failure.
Discussion
In humans, there are now examples of specific CP func-
tions that fail as a result of inherited and acquired con-
ditions. For example, there are two different genetic
causes of inability to pump MeTHF from blood into
CSF via CP. These can be termed human knockouts
(KOs). This can be due to KO of either FRa or PCFT
[1,3]. These human KOs, as expected, have cerebral
folate deficiency (CFD) and devastating neurological
syndromes. An acquired cause of CFD is the formation
of antibodies to the FRa [1]. On the other hand, KO of
* Correspondence: Conrad_Johanson@brown.edu
2Department of Neurosurgery, Alpert Medical School at Brown University,
Providence, RI, 02903 USA
Full list of author information is available at the end of the article
Spector and Johanson Cerebrospinal Fluid Research 2010, 7:14
http://www.cerebrospinalfluidresearch.com/content/7/1/14
CEREBROSPINAL FLUID RESEARCH
© 2010 Spector and Johanson; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
SVCT-2 (that transports AA into CSF) in animals and
humans is not compatible with life [1].
The above examples are extremely revealing but do
not answer the question about generalized CP failure -
akin to renal failure - secondary to diffuse damage to
the CP epithelial cells [2]. However, in recent years, a
specific example of CP failure has been described in
KSS [4-9]. KSS is caused by various abnormalities of the
mitochondrial genome, often due to deletions of ~5 kb
[4-9]. KSS often manifests itself with progressive exter-
nal ophthalmoplegia, pigmented retinopathy, heart
block, elevated CSF protein and cerebellar ataxia. How-
ever, the deletions or other DNA abnormalities do not
interfere with the abnormal mitochondrial DNA’s ability
to replicate [4-8]. In humans, the normal mitochondrial
genome is a circular double-stranded DNA helix of
16.5 kb that encodes 13 polypeptides and 22 t-RNAs
and 2 ribosomal RNAs [8]. There are 2-10 copies of
circular DNA per mitochondrion, an organelle that
turns over ~ every 30 days. In the KSS syndrome during
very early development, a deletion (or other abnormal-
ity) occurs in the mitochondrial DNA that is propagated
in various tissues (heteroplasmy) like CP and muscle [8].
Heteroplasmy is defined as the presence of both normal
and abnormal circular DNA double helices in mitochon-
dria in a cell. When the heteroplasmy reaches ~30% or
more abnormal DNA circles in the mitochondria of a
cell, there are changes in that cell’s structure and func-
tion due to the abnormal mitochondrial DNA [4-8]. As
might be expected, sufficient heteroplasmy would lead
to insufficient ATP production, a principal function of
mitochondria.
In KSS, there are prominent anatomical changes in
human CP epithelial cells that are greatly enlarged and
full of eosinophilic granules [4]. In vivo, in humans with
KSS one known functional consequence is the inability
to transport adequate amounts of MeTHF into CSF
with consequent CFD [4-7,9]. Most patients have extre-
mely low MeTHF CSF concentrations even in the face
of a normal plasma concentration [4-7,9]. In one series
of patients (N = 6), the average CSF MeTHF concentra-
tion was 8 nM (normal range 50-134 nM) with an aver-
age plasma folate concentration of 17 nM (normal range
10-30 nM) [9].
Unlike MeTHF, the HVA concentrations in CSF are ele-
vated in KSS (by about a factor of 2 above the upper limit
of normal, N = 6) almost certainly due to decreased clear-
ance of HVA from CSF, presumably by the CP epithelial
OAT-3 [6,9]. There is no evidence for increased dopamine
turnover in brain that would also explain the increased
CSF HVA concentration [9]. One hypothesis for these
abnormalities in KSS is inadequate provision of energy
substrate (ATP) that drives the CSF-inward transport of
MeTHF and the CSF-outward transport of HVA [10,11].
However, other potential explanations are possible. What
is certain, though, is that an inward CP transport system
(MeTHF) and an outward clearance system (HVA) are
abnormal in KSS. Another abnormality in KSS is an ele-
vated CSF protein. We posit that the increased protein
concentration could result from leaky CP tight junctions
or reduced CSF turnover rate (bulk flow) that results from
curtailed ATP-driven CSF formation [10].
Associated with the low CSF MeTHF and the raised
HVA and CSF protein in KSS, is a devastating progres-
sive neurological disorder that begins before the age of
twenty. KSS manifests itself clinically with ophthalmo-
plegia, retinopathy, ataxia and other abnormalities [4-7].
We postulate that the disease (KSS) begins to manifest
itself when the heteroplasmy (abnormal mitochondrial
DNA) reaches a threshold value [11]. In several cases,
treatment with very high doses of reduced folate, with
normalization of CSF MeTHF, has been beneficial - pre-
sumably ameliorating the CFD [4-7]. However, MeTHF
treatment only partially reverses the signs and symp-
toms of KSS [4-7].
Thus, KSS can be considered a cause of diffuse CP
failure. Presumably, beside MeTHF and HVA transport,
many other important functions are abnormal. For
example, we would predict AA concentrations in CSF
will be low. Hence, if in fact the concentration of AA is
low in CSF, KSS patients might benefit from high doses
of intravenous dehydroascorbic acid (DHA). DHA enters
brain via the glucose transporter at the blood- brain bar-
rier (via the transporter glut 1) and is converted to AA
in situ in brain [1].
Conclusion
KSS is an example of a systemic mitochondrial disorder
that affects the CP anatomically and physiologically. It is
clear that the CP, like several other tissues (e.g., muscle)
in KSS, suffers from excess mitochondrial DNA hetero-
plasmy. This presumably leads to insufficient ATP con-
centrations to drive cellular processes (e.g., active
transport) in CP with consequent low CSF and CNS
MeTHF concentrations, as well as elevated CSF HVA,
and other so-far unmeasured CSF abnormalities. Our
increased understanding of KSS has led to amelioration
of the syndrome (with high doses of reduced folates),
but there is clearly more work to be done. KSS is an
example of the importance of basic research in unravel-
ing complex clinical disorders.
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